Medical Crossfire®: Personalized Regimens for Managing Hemophilia A: Selecting an Optimal Recombinant FVIII Agent
January 5, 2022
January 5, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — 1.5 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward hematologists, primary care clinicians, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the management of hemophilia.
Over the past 20 years, substantial advances in the treatment of hemophilia A have allowed patients to take greater control of their disease. The primary goals of hemophilia A treatment are to prevent bleeding episodes, reduce long-term complications of bleeding, and arrest bleeding if it occurs. Health care providers should understand the underlying etiology and pathophysiology of hemophilia A. In addition, providers should be familiar with how patients perceive their disease and how health-related and economic burdens of hemophilia A impact patients and their families.
Upon completion of this activity, you should be better able to:
- Explain the role of FVIII therapy in managing bleeding in patients with hemophilia A
- Evaluate clinical trial data for new and emerging recombinant FVIII products for the prophylactic treatment of patients with hemophilia A
- Discuss the role of pharmacokinetic-tailored prophylaxis in selecting a recombinant FVIII product for the management of hemophilia A
- Develop personalized prophylactic treatment plans for patients with hemophilia A
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Medical Director, Pediatric Hemophilia and Coagulation Disorders Program
Medical Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI
Kenneth A. Bauer, MD
Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
Michelle L. Witkop, DNP, FNP-BC
Head of Research
Vice President, Research Strategy
National Hemophilia Foundation
New York, NY
Physician Accreditation Statement
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Disclosures of Conflicts of Interest
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Steven W. Pipe, MD
- Grant/Research Support: Siemens, YewSavin
- Consultant: ApcinteX, ASC Therapeutics, Bayer Healthcare, BioMarin Pharmaceutical, Catalyst Biosciences, CSL Behring, GeneVentiv Therapeutics, HEMA Biologics, Freeline Therapeutics, Novo Nordisk, Pfizer, F. Hoffmann-La Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda Pharmaceutical Company, Spark Therapeutics, uniQure
Kenneth A. Bauer, MD has no relevant financial relationships with ineligible companies.
- Michelle L. Witkop, DNP, FNP-BC
- Consultant: F. Hoffmann-La Roche.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.